Literature DB >> 21339365

MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4.

Caglar Cekic1, Carolyn R Casella, Duygu Sag, Frann Antignano, Joseph Kolb, Jill Suttles, Michael R Hughes, Gerald Krystal, Thomas C Mitchell.   

Abstract

We previously showed that monophosphoryl lipid A (MLA) activates TLR4 in dendritic cells (DCs) in a Toll/IL-1R domain-containing adaptor inducing IFN-β (TRIF)-biased manner: MLA produced from Salmonella minnesota Re595 induced signaling events and expression of gene products that were primarily TRIF dependent, whereas MyD88-dependent signaling was impaired. Moreover, when tested in TRIF-intact/MyD88-deficient DCs, synthetic MLA of the Escherichia coli chemotype (sMLA) showed the same activity as its diphosphoryl, inflammatory counterpart (synthetic diphosphoryl lipid A), indicating that TRIF-mediated signaling is fully induced by sMLA. Unexpectedly, we found that the transcript level of one proinflammatory cytokine was increased in sMLA-treated cells by MyD88 deficiency to the higher level induced by synthetic diphosphoryl lipid A, which suggested MyD88 may paradoxically help restrain proinflammatory signaling by TRIF-biased sMLA. In this article, we demonstrate that sMLA induces MyD88 recruitment to TLR4 and activates the anti-inflammatory lipid phosphatase SHIP1 in an MyD88-dependent manner. At the same time, MyD88-dependent signaling activity at the level of IL-1R-associated kinase 1 is markedly reduced. Increased SHIP1 activity is associated with reductions in sMLA-induced IκB kinase α/β and IFN regulatory factor 3 activation and with restrained expression of their downstream targets, endothelin-1 and IFN-β, respectively. Results of this study identify a pattern that is desirable in the context of vaccine adjuvant design: TRIF-biased sMLA can stimulate partial MyD88 activity, with MyD88-dependent SHIP1 helping to reduce proinflammatory signaling in DCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21339365      PMCID: PMC3249415          DOI: 10.4049/jimmunol.1001034

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  SHIP is required for dendritic cell maturation.

Authors:  Frann Antignano; Mariko Ibaraki; Connie Kim; Jens Ruschmann; Angela Zhang; Cheryl D Helgason; Gerald Krystal
Journal:  J Immunol       Date:  2010-02-12       Impact factor: 5.422

Review 2.  Regulation of the immune response by SHIP.

Authors:  Michael E March; Kodi Ravichandran
Journal:  Semin Immunol       Date:  2002-02       Impact factor: 11.130

3.  SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.

Authors:  M Sattler; S Verma; Y B Pride; R Salgia; L R Rohrschneider; J D Griffin
Journal:  J Biol Chem       Date:  2000-10-12       Impact factor: 5.157

4.  Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant.

Authors:  Paul Baldrick; Derek Richardson; Gary Elliott; Alan W Wheeler
Journal:  Regul Toxicol Pharmacol       Date:  2002-06       Impact factor: 3.271

5.  Alteration of Toll-like receptor 4 activation by 4-hydroxy-2-nonenal mediated by the suppression of receptor homodimerization.

Authors:  Yoon Sun Kim; Zee Yong Park; So Young Kim; Eunshil Jeong; Joo Young Lee
Journal:  Chem Biol Interact       Date:  2009-07-21       Impact factor: 5.192

6.  Inositol phosphatase SHIP1 is a primary target of miR-155.

Authors:  Ryan M O'Connell; Aadel A Chaudhuri; Dinesh S Rao; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

Review 7.  Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

Authors:  Jay T Evans; Christopher W Cluff; David A Johnson; Michael J Lacy; David H Persing; Jory R Baldridge
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

8.  Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A.

Authors:  Caglar Cekic; Carolyn R Casella; Chelsea A Eaves; Atsushi Matsuzawa; Hidenori Ichijo; Thomas C Mitchell
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

9.  SHIP1 is a repressor of mast cell hyperplasia, cytokine production, and allergic inflammation in vivo.

Authors:  D James Haddon; Frann Antignano; Michael R Hughes; Marie-Renée Blanchet; Lori Zbytnuik; Gerald Krystal; Kelly M McNagny
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

10.  Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas.

Authors:  Irene M Pedersen; Dennis Otero; Elaine Kao; Ana V Miletic; Christoffer Hother; Elisabeth Ralfkiaer; Robert C Rickert; Kirsten Gronbaek; Michael David
Journal:  EMBO Mol Med       Date:  2009-08       Impact factor: 12.137

View more
  19 in total

Review 1.  microRNAs in the regulation of dendritic cell functions in inflammation and atherosclerosis.

Authors:  Martin Busch; Alma Zernecke
Journal:  J Mol Med (Berl)       Date:  2012-02-04       Impact factor: 4.599

2.  Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.

Authors:  Caglar Cekic; Yuan-Ji Day; Duygu Sag; Joel Linden
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

3.  Monophosphoryl lipid A inhibits the cytokine response of endothelial cells challenged with LPS.

Authors:  Ryan Stark; Hyehun Choi; Stephen Koch; Fred Lamb; Edward Sherwood
Journal:  Innate Immun       Date:  2014-12-24       Impact factor: 2.680

Review 4.  Cell-intrinsic and -extrinsic roles of miRNAs in regulating T cell immunity.

Authors:  Sunglim Cho; Jiayi Dong; Li-Fan Lu
Journal:  Immunol Rev       Date:  2021-09-21       Impact factor: 12.988

5.  Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo.

Authors:  Grant R Stenton; Lloyd F Mackenzie; Patrick Tam; Jennifer L Cross; Curtis Harwig; Jeffrey Raymond; Judy Toews; David Chernoff; Thomas MacRury; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

6.  Effects of Differences in Lipid A Structure on TLR4 Pro-Inflammatory Signaling and Inflammasome Activation.

Authors:  Paula M Chilton; Chelsea A Embry; Thomas C Mitchell
Journal:  Front Immunol       Date:  2012-06-13       Impact factor: 7.561

Review 7.  Immunopharmacology of lipid A mimetics.

Authors:  William S Bowen; Siva K Gandhapudi; Joseph P Kolb; Thomas C Mitchell
Journal:  Adv Pharmacol       Date:  2013

8.  Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A.

Authors:  Carolyn R Casella; Thomas C Mitchell
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

9.  Extracellular adenosine regulates naive T cell development and peripheral maintenance.

Authors:  Caglar Cekic; Duygu Sag; Yuan-Ji Day; Joel Linden
Journal:  J Exp Med       Date:  2013-10-21       Impact factor: 14.307

10.  In vivo and in vitro characterization of the immune stimulating activity of the Neisserial porin PorB.

Authors:  Andrew Platt; Heather MacLeod; Paola Massari; Xiuping Liu; Lee Wetzler
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.